Company Overview of Intersect ENT, Inc.
Intersect ENT, Inc., a commercial stage drug-device company, provides therapeutic solutions for patients with ear, nose, and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.
1555 Adams Drive
Menlo Park, CA 94025
Founded in 2003
Key Executives for Intersect ENT, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $332.4K
Chief Financial Officer and Principal Accounting Officer
Total Annual Compensation: $202.8K
Chief Operating Officer and Senior Vice President
Total Annual Compensation: $290.2K
Vice President of Sales
Total Annual Compensation: $154.5K
Compensation as of Fiscal Year 2014.
Intersect ENT, Inc. Key Developments
Intersect ENT, Inc. Announces Board Appointments
Apr 10 15
Intersect ENT, Inc. announced the appointment of Kieran T. Gallahue and W. Anthony Vernon to the company's board of directors. Mr. Gallahue will serve as lead director and a member of the audit committee and Mr. Vernon will serve as chair of the nominating and corporate governance committee. Additionally, current director Casper de Clerq from Norwest Venture Partners has informed the board of directors that he will not seek re-election at the annual stockholder meeting in June. Kieran Gallahue most recently served as chairman and CEO of CareFusion. Tony Vernon recently retired as CEO of Kraft Foods Group, Inc.
Intersect ENT, Inc. Reports Unaudited Consolidated Financial Results for the Fourth Quarter and Year Ended December 31, 2014
Feb 26 15
Intersect ENT, Inc. reported unaudited consolidated financial results for the fourth quarter and year ended December 31, 2014. Revenue for the three months ended December 31, 2014 increased by 93% to $13.4 million from $7.0 million in the same period in 2013. This increase is attributable to higher unit sales via the acquisition of new accounts and driving adoption with existing customers. Net loss for the fourth quarter of 2014 improved to $3.7 million compared to $4.6 million for the fourth quarter of 2013. Fourth quarter basic and diluted LPS were $0.16 a share against $2.64 a year ago. Loss from operations was $3.686 million against $4.445 million a year ago.
Revenue for the year ended December 31, 2014 increased by 115% to $38.6 million from $17.9 million in the same period in 2013. This increase is attributable to higher unit sales via acquisition of new accounts and expanded adoption by existing customers, and was supported by expansion of the company’s sales force. Net loss for the year was consistent with the prior year, with a net loss of $18.4 million for each of the years 2014 and 2013. Basic and diluted LPS for 2014 were $1.61 against $12.57 a year ago. Loss from operations was $18.078 million against $17.966 million a year ago.
Intersect ENT, Inc. Presents at 27th Annual ROTH Conference, Mar-10-2015 03:00 PM
Feb 13 15
Intersect ENT, Inc. Presents at 27th Annual ROTH Conference, Mar-10-2015 03:00 PM. Venue: The Ritz Carlton, 1 Ritz Carlton Dr, Dana Point, CA 92629, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|